Garuda - Garba Rujukan Digital

p-Index From 2019 - 2024

2.522

P-Index

This Author published in this journals

All Journal Folia Medica Indonesiana Indonesian Journal of Tropical and Infectious Disease Majalah Kesehatan FKUB Jurnal Respirologi Indonesia Jurnal Respirasi (JR) Jurnal Ilmiah Akuntansi dan Bisnis JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga JOURNAL OF COMMUNITY MEDICINE AND PUBLIC HEALTH RESEARCH Indian Journal of Forensic Medicine & Toxicology Jurnal Perak Malahayati : Pengabdian Kepada Masyarakat Ophthalmologica Indonesiana JUMANTIK (Jurnal Ilmiah Penelitian Kesehatan)

Laksmi Wulandari

Departement Of Pulmonology, Faculty Of Medicine, Airlangga University

Author-ID : 3289685

Biochemistry, Genetics & Molecular Biology Earth & Planetary Sciences Economics, Econometrics & Finance Environmental Science Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Physics Public Health Other

Published : 27 Documents Claim Missing Document

Claim Missing Document

Articles

Title

LYMPHOCYTE-T TYPE TH1 AND TH2 ACTIVITY DIFFERENCE OF LUNG TISSUE ON Heligmosomoides polygyrus NEMATODE AND Mycobacterium tuberculosis SEQUENTIAL CO-INFECTION Laksmi Wulandari; Muhammad Amin; Soedarto Soedarto; Gatot Soegiarto
Folia Medica Indonesiana Vol. 53 No. 2 (2017): JUNE 2017
Publisher : Faculty of Medicine, Universitas Airlangga

Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium tuberculosis that are often associated with uneffectiveness of the BCG vaccine and the high worm infection. The objective of this study was to determine the differences in the activity of Limfosit T type Th1 (IFN-g) and Th2 (IL-4) in lung tissue on Heligmosomoides polygyrus nematode and Mycobacterium tuberculosis sequential co-infection. This research using 49 mice were divide into 7 groups treated with infection by Mycobacterium tuberculose inhaled and Heligmosomoides polygyrus orally within 8 and 16 weeks. The levels of IFN-g in peripheral blood serum (89.929 + 3.533 pg/mL) resembles the pattern of the percentage of lymphocytes T CD4+ Th1 in lung tissue (3.246 + 0.519%) and peripheral blood (4.950 + 0.237%), while the levels IL-4 in the peripheral blood serum (20.782 + 4.043%) resembles the pattern of the percentage of lymphocytes T CD4+ Th2 in intestinal tissue (1.048 + 0.359%) and peripheral blood (1.196 + 0.557%). In conclusion, there is difference in the activity of lymphocytes T type Th1 and Th2 but it does not affect the immune response to Mycobacterium tuberculosis infection.

COMPARISON OF CHEMOTHERAPY RESPONSE AND ADVERSE EFFECTS OF DOUBLE-PLATINUM PLUS EGFR-TKI VERSUS DOUBLE-PLATINUM ALONE ON NSLCLC PATIENTS WITH DISEASE PROGRESSION AND EGFR-TKI TREATMENT Laksmi Wulandari; Edward Pandu Wiriansya
Folia Medica Indonesiana Vol. 53 No. 4 (2017): December 2017
Publisher : Faculty of Medicine, Universitas Airlangga

EGFR-TKI is the first-line therapy for EGFR-mutant patients. Nevertheless, patients will have disease progression (median PFS 10 – 12 months) due to resistance. The treatment options are still limited in developing countries for such cases, thus double-platinum chemotherapy is the next option. Although IMPRESS study reported no difference in terms of PFS and OS between double-platinum alone and double-platinum plus EGFR-TKI, several local studies reported benefit of continuing EGFR-TKI in combination with double-platinum chemotherapy (treatment beyond progression). This study aimed to compare chemotherapy effects of double-platinum plus EGFR-TKI versus double-platinum alone on patients with NSCLC progression after EGFR-TKI treatment. This was an analytical descriptive study using prospective cohort design, involving 30 patients with disease progression following EGFR-TKI treatment that met inclusion criteria in Dr. Soetomo Hospital. Subjects were divided into two groups: arm A (double-platinum plus EGFR-TKI) and arm B (double-platinum alone). Subjects were observed until 4 cycles of double-platinum chemotherapy. Subjective response (body weight and EQ5D questionnaire) was analyzed, chest CT scans were evaluated using RECIST criteria, and adverse effects were monitored. This study was conducted in accordance with GCP principles and has received ethics certificate from Dr. Soetomo Hospital ethics committee (No. 08/Panke.KKE/I/2017). The results showed that subject characteristics between two arms were insignificantly different (p=0.05). The most common EGFR mutation was exon 21 (50% on arm A and 60% on arm B). Chi square was tested on subjective response parameter (EQ5D (p=0.483)). T2 free sample was tested on semi-subjective parameter (body weight (p=1.00)). Comparison test on both groups after cycle 2 and 4 showed p value=0.05. Statistical test on adverse effect between both groups showed p value=0.526. As a conclusion, there was no significant difference between double-platinum and double-platinum plus EGFR-TKI on patients who had disease progression following EGFR-TKI treatment.

Case report: Management of Progressive Lung Cancer Patients after First-Line EGFR Tyrosine Kinase Inhibitor Therapy Sahrun Sahrun; Laksmi Wulandari
Folia Medica Indonesiana Vol. 55 No. 3 (2019): September
Publisher : Faculty of Medicine, Universitas Airlangga

Various tyrosine kinase inhibitor (TKI) drugs have been widely used as therapy for cancer that has EGFR mutations, or abnormal EGFR activation. However, patients who have a mutation in the gene that activates EGFR only benefit from EGFR-TKI therapy for less than one year, because after that resistance occurs. In the management of patients according to NCCN 2017, patients who experience progress after receiving TKI as the first-line therapy must undergo an examination to identify the presence of T790M mutation. If the T790M mutation is positive, the choice of therapy that needs to be provided is the third generation (Osimertinib). Many recent studies have proved the significance of the effectiveness and response of Osimertinib therapy in lung cancer with EGFR T790M mutation. We reported the management of a pulmonary adenocarcinoma patient with positive EGFR mutation who had received first-line EGFR TKI who had progressive disease and T790M mutation in Dr. Seotomo Hospital. The patient finally received Osimertinib through an Early Access Program with a therapeutic response that improved significantly.

Mediastinal Non-Hodgkin's Lymphoma Metastatic to Right Atrium Mimicking Right Atrial Myxoma Gemilang Khusnurrokhman; Laksmi Wulandari
Folia Medica Indonesiana Vol. 57 No. 4 (2021): December
Publisher : Universitas Airlangga

Highlight:A 32-year-old male patient suffered mediastinal non-hodgkin's lymphoma metastatic to the right atrium which mimicked right atrial myxoma.The patient died of suspected mediastinal NHL thromboembolism that spread in the right atrium. Abstract:In this case report, the anatomical pathology results in the form of B cell type LNH, but at the age of 32 years and the risk factor in this patient was a former active smoker. In the anatomical pathology results, the results of the B-High Grade Cell Type LNH were also obtained. B-cell type non-hodgkin’s lymphoma can be mutated in the MYC gene (v-myc avian myceloctomatosis viral oncogene homolog) and the BCL-2 and BCL-6 (B-cell lymphoma) genes. If this morphology is found, then the patient's prognosis is poor. Most of these patients were males and the incidence was in the mediastinal area. Mediastinal NHL could develop and enlarge to involve the heart and pericardium. The spread could occur directly and lymphogens. These metastatic tumors were often misdiagnosed with atrial myxoma. In this case report, exploration of the right atrium and open mediastinal biopsy was performed. An open biopsy of the mediastinum revealed a mediastinal mass that enlarged to enter the right atrium. Atrial myxoma was not found. Primary lymphoma growth could also occur in the heart. This condition was called primary cardiac lymphoid (PCL). This case was very rare and was often considered an atrial myxoma. The patient died 10 days after discharge from the hospital. While the patient was eating, the patient had a seizure and the patient was immediately taken to the emergency department of Dr. Soetomo General Academic Hospital, Surabaya, and entered the ER (Resuscitation) ER room, but the patient died after being assisted for approximately two hours. Most likely the cause of the patient's death was a thromboembolic tumor in the right atrium that was released, so that it entered the bloodstream of the brain, causing the patient to have seizures. It was suspected that the cause of the patient's death was the presence of a tumor thrombus that separated into an embolism from the right atrium due to the large size of the tumor. Patients suffering from high rate NHL had a greater percentage of suffering from tumor thromboembolism as many as 10.6% compared to the Low type and Hodgkins lymphoma (LH) (5.8% and 7.25%).

A 28-Year-Old Man With Mediastinal Seminoma Treated With BEP Agustinus Rizki; Laksmi Wulandari
Folia Medica Indonesiana Vol. 57 No. 4 (2021): December
Publisher : Universitas Airlangga

Highlight:A 28-year-old male suffered chylothorax and mediastinal seminoma.The patient received bleomycin, etoposide and cisplatin chemotherapy for the management of mediastinal seminomas but he died beforeundergoing 5th cycle chemotherapy. Abstract:Seminoma is a type of germ cell tumor. In this case presentation, a rare primary germ cell tumor was reported in the form of mediastinal seminoma. A 28-year-old man with symptoms of shortness of breath, chest pain, swelling in the right upper extremity, enlarged lymph nodes in the colli region. Thoracic physical examination revealed signs of pleural fluid in the right hemithorax. After obtaining the results of radiological and pathological investigations, a mediastinal mass was obtained, then BEP chemotherapy was given. After 3 cycles of chemotherapy, a partial response was obtained. Patients with mediastinal seminoma treated with BEP base chemotherapy gave a partial response.

Co-Authors Agustinus Rizki Aldise M Nastri Aldise Mareta Aldise Mareta Nastri Aldise Mareta, Aldise Ana Rima Andreas Infianto Anna Febriani Arif Santoso Aris Widayati Arta Rahman Ayu Rahmanita Putri Soetrisno Barizatul Husniyah Bonfilio Neltio Ariobimo Dana Hendrawan Putra Djoko Poetranto Djoko Poetranto, Djoko Edith Frederika Edith Frederika, Edith Elisna Syahruddin Emmanuel Djoko Poetranto Ermayanti, Sabrina Erwin Winaya Evelyn Asaleo Ferry Dwi Kurniawan Gatot Soegiarto Gatot Soegiarto Gemilang Khusnurrokhman Gilang Muhammad Setyo Nugroho Grahana Ade Candra Wolayan Gusti Agung Ayu Ira Kencana Dewi Haryati Haryati Hendra Ikhwan Gautama Ida Ayu Jasminarti Indana Eva Ajmala Jamal Zaini Kazufumi Shimizu Khansa Fahira Wisdana Kusdiantoro Kusdiantoro Kusdiantoro Kusdiantoro Landia Setiawati Linda Dewanti Lu'lu'il Maqnun Lucia Landia Setyowati Lucia Landia Setyowati, Lucia Landia Luh Ade Wilan Krisna Lukisiari Agustini Masaoki Yamaoka Masaoki Yamaoka Masaoki Yamaoka, Masaoki Monica Tiara Arum Kinanthi Muhammad Amin Muhammad Fitra Ramadhan Nadira Putri Nastiti Nathaniel Aditya Neni Daniati Nikson Eduard Faot Nina Mauthia Noni Novisari Soeroso Prima Ardiansah Surya Pudji Lestari Putri Mega Juwita Rebekah Setiabudi, Rebekah Resti Yudhawati Retno A Setyoningrum Retno Asih Retno Asih Setyoningrum Risnawati Risnawati Sacharissa Zerlina Tsarwah Thirafi Sahrun Sahrun Setyawan, Ungky Agus Sita Andarini Sita Ro'yul Aini Sjahjenny Mustokoweni, Sjahjenny Soedarto Soedarto Sri Melati Munir Sulistiawati Sulistiawati Susilowati Andajani, Susilowati Suwandi Triadi Putra Paladan Utami Meilanie Putri Veda Septian Cahya Budi Wibi Riawan Wiriansya, Edward Pandu Wiwin Is Effendi Yolanda Ayu Yashinta Zahira Pelangi Rahmadilla Satriadi Zaphiria Loka Pramesthi Zaufy Verlieza Oktaviano Subagyo

Title Search

Found 5 Documents Search Journal : Folia Medica Indonesiana

Abstract

Abstract

Abstract

Abstract

Abstract

Title

Found 5 Documents
Search
Journal : Folia Medica Indonesiana